Autoimmune & Rheumatology Clinical Trials Update: Week 33, 2026

Published August 14, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

A Study of Outcomes in Chinese Patients Treated With Anifrolumab Who Have Active Mod-severe Systemic Lupus Erythematosus

This Phase 3 study is exploring the use of anifrolumab, an immunotherapy, in Chinese patients with moderate to severe systemic lupus erythematosus (SLE). The goal is to help patients achieve better disease remission and reduce the use of steroids, which are often linked to side effects. Results from this large trial, involving 417 patients across China, could lead to improved treatment options for people living with lupus.

JAK Inhibitor Dose TAPering Strategy Study

This Phase 4 study is investigating whether patients with rheumatoid arthritis who have their disease under good control can safely reduce their doses of JAK inhibitors. Lowering medication doses may help reduce side effects and the burden of taking medication regularly. The study is enrolling 308 participants in France and involves regular visits to monitor disease activity and safety during the tapering process.

Efficacy of A Non-Invasive Botulinum Toxin Microneedle Pad for the Treatment of Secondary Raynaud's Phenomenon

This upcoming Phase 3 trial will test a new non-invasive treatment using a botulinum toxin microneedle pad for people with systemic sclerosis who experience Raynaud’s phenomenon. This condition causes painful symptoms in the fingers and toes due to poor blood flow. The new treatment aims to be less painful and easier to use than traditional injections, potentially improving hand function and comfort for patients.

GLP-1s in Hip and Knee Arthroplasty

This Phase 4 study is looking at whether GLP-1 receptor agonists can help overweight or obese adults awaiting hip or knee replacement surgery for arthritis. The trial will assess if this medication improves pain management and recovery after surgery. With 100 participants in Canada, this research may offer new ways to support joint surgery outcomes for people with obesity-related arthritis.

Impact of Glucagon-like Peptide-1 (GLP-1) Analogs on Disease Outcomes in Psoriatic Arthritis: A Pragmatic Randomized Controlled Trial

This Phase 4 trial is comparing GLP-1 analog medications to nutrition counseling in adults with psoriatic arthritis who also have obesity and type 2 diabetes. The research aims to find better treatment strategies that improve joint symptoms and overall disease management. The study is recruiting in the United States and will run for about 24 weeks with several clinic visits.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.